https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50489 Wed 28 Feb 2024 15:28:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54152 Wed 28 Feb 2024 15:03:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24335 3 months (222 pain patients and 204 opioid substitution therapy (OST) patients). We employed item and scale psychometrics (exploratory factor analyses, confirmatory factor analyses and item-response theory statistics) to refine items to a brief scale. Results: Following removal of problematic items (poor retest-reliability or wording, semantic redundancy, differential item functioning, collinearity or rarity) iterative factor analytic procedures identified a 10-item unifactorial scale with good model fit in the total sample (N= 426; CFI = 0.981, TLI = 0.975, RMSEA = 0.057), and among pain (CFI = 0.969, TLI = 0.960, RMSEA = 0.062) and OST subgroups (CFI = 0.989, TFI = 0.986, RMSEA = 0.051). The 10 items provided good discrimination between groups, demonstrated acceptable test-retest reliability (ICC 0.80, 95% CI 0.60-0.89; Cronbach's alpha = 0.89), were moderately correlated with related constructs, including opioid dependence (SDS), depression and stress (DASS subscales) and Social Relationships and Environment domains of the WHO-QoL, and had strong face validity among advising clinicians. Conclusions: The Opioid-Related Behaviours In Treatment (ORBIT) scale is brief, reliable and validated for use in diverse patient groups receiving opioids. The ORBIT has potential applications as a checklist to prompt clinical discussions and as a tool to quantify aberrant behaviour and assess change over time.]]> Wed 24 Nov 2021 15:52:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38219 Wed 18 Aug 2021 09:45:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42037 Wed 17 Aug 2022 12:13:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38380 Wed 12 Jan 2022 15:50:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55236 Wed 01 May 2024 15:39:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39851 .05). Objective sleep onset latency increased from the Baseline to the Treatment phase in the control (stretching) group (p = .042). In contrast, the Cycling group exhibited improvements in sleep duration (p = .008) and sleep efficiency (p = .023) during the Treatment phase compared to the Baseline phase. Cycling also increased sleep duration (p = .005), decreased average wake bout (p = .040) and tended to increase sleep efficiency (p = .051) compared to stretching during the Treatment phase. Subjective sleep quality ratings did not differ between groups (p > .10). These preliminary findings suggest that moderate-intensity aerobic exercise may attenuate the sleep disturbances associated with cannabis withdrawal.]]> Tue 26 Jul 2022 09:52:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49530 Tue 23 May 2023 12:12:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21585 Tue 17 Nov 2015 14:40:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55154 Tue 16 Apr 2024 15:25:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38188 Tue 10 Aug 2021 15:11:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43825 Tue 04 Oct 2022 11:04:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36681 Thu 27 Jan 2022 15:57:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52634 Thu 19 Oct 2023 15:11:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10864 Sat 24 Mar 2018 08:12:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17220 Sat 24 Mar 2018 07:59:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17227 Sat 24 Mar 2018 07:59:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19389 Sat 24 Mar 2018 07:52:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18578 Sat 24 Mar 2018 07:50:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30941 Sat 24 Mar 2018 07:33:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23860 Sat 24 Mar 2018 07:12:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44139 r = 0.40–0.52) and ATOP Physical Health with SF-36 Physical Components and SF-36 General Health scores (r = 0.36–0.67). The ATOP Quality of Life scale showed moderate agreement with the SDS and six-dimensional health state short form scales (r = 0.38–0.40). ATOP substance use, employment, education and child care items showed good to excellent interrater reliability (Krippendorff's α = 0.62–0.81), and tobacco use, Psychological Health, Physical Health and Quality of Life showed fair to moderate interrater reliability (Krippendorff's α Sat 08 Oct 2022 12:43:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44760 Mon 24 Oct 2022 08:49:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44538 Mon 17 Oct 2022 09:03:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50976 Mon 14 Aug 2023 15:25:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50937 Mon 14 Aug 2023 12:58:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51584 Mon 11 Sep 2023 14:36:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52301 Mon 09 Oct 2023 10:16:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46876 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) and were seeking treatment, were nonresponsive to prior treatment attempts, were 18 to 64 years of age, had no other substance use disorder, had no severe medical or psychiatric conditions, were not pregnant, were not mandated by a court to undergo treatment, and provided informed consent. Results for primary efficacy measures and all secondary outcomes were obtained using a modified intention-to-treat data set. Interventions: Participants received 12-week treatment involving weekly clinical reviews, structured counseling, and flexible medication doses - up to 32 sprays daily (tetrahydrocannabinol, 86.4 mg, and cannabidiol, 80 mg), dispensed weekly. Main Outcomes and Measures: Primary outcome was self-reported number of days using illicit cannabis during the 12-week period. Other outcomes included alternate cannabis use parameters (periods of abstinence, withdrawal, cravings, and problems), safety parameters (adverse events and aberrant medication use), health status, other substance use, and treatment retention. Results: A total of 128 participants (30 women and 98 men; mean [SD] age, 35.0 [10.9] years) were randomized and received at least 1 dose of study medication. Participants had used a mean (SD) of 2.3 (2.1) g of cannabis on a mean (SD) of 25.7 (4.5) days in the past 28 days. Treatment retention was comparable for the 2 groups (placebo, 30 of 67 participants [44.8%]; nabiximols, 30 of 61 participants [49.2%]), and both groups used similar mean (SD) doses (placebo, 18.5 [9.5] sprays daily; nabiximols, 17.6 [9.5] sprays daily, equivalent to a mean [SD] of 47.5 [25.7] mg of tetrahydrocannabinol and 44.0 [23.8] mg of cannabidiol). For the primary end point, the placebo group reported significantly more days using cannabis during the 12 weeks (mean [SD], 53.1 [33.0] days) than the nabiximols group (mean [SD], 35.0 [32.4] days; estimated difference, 18.6 days; 95% CI, 3.5-33.7 days; P =.02). Both groups showed comparable improvements in health status, with no substantial changes in other substance use. Medication was well tolerated with few adverse events. Conclusions and Relevance: This study demonstrates that cannabinoid agonist treatment, in this case using nabiximols, in combination with psychosocial interventions is a safe approach for reducing cannabis use among individuals with cannabis dependence who are seeking treatment. Trial Registration: anzctr.org.au Identifier: ACTRN12616000103460.]]> Mon 05 Dec 2022 09:33:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46800 Mon 05 Dec 2022 08:29:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47241 Fri 16 Dec 2022 12:15:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47240 Fri 16 Dec 2022 12:15:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30423 Fri 03 Dec 2021 10:34:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49822 Fri 02 Jun 2023 16:30:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23970 -1 (mean: 564 mg; 95% confidence interval 431-696 mg). Median buprenorphine dose was 12.0 mg (interquartile range 9.5 mg, range 4-32 mg) at day 7 and 16.0 mg (interquartile range 13.5 mg, range 4-32 mg) at day 28. Buprenorphine doses received were markedly higher than estimated codeine doses based on standard dose conversion tables.Discussion and Conclusions: With increasing presentations relating to codeine dependence, these findings provide important guidance to clinicians. Buprenorphine doses were consistently higher than doses estimated based on the dose of codeine consumed, and were comparable with doses used in the treatment of dependence with heroin and more potent prescription opioids.]]> Fri 01 Apr 2022 09:28:10 AEDT ]]>